Sutro Biopharma STRO Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →
Ask your AI about Sutro Biopharma's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Sutro Biopharma's additional paid-in capital?
- Sutro Biopharma (STRO) reported additional paid-in capital of $949.64M in Q1 2026.
- How has Sutro Biopharma's additional paid-in capital changed year-over-year?
- Sutro Biopharma's additional paid-in capital increased by 13.5% year-over-year, from $836.95M to $949.64M.
- What is the long-term trend for Sutro Biopharma's additional paid-in capital?
- Over 5 years (2020 to 2025), Sutro Biopharma's additional paid-in capital has grown at a 8.6% compound annual growth rate (CAGR), from $559.75M to $845.48M.
- What does additional paid-in capital mean?
- This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.